Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

New Cancer Research Microarray Detects CNVs and LOH on a Single Chip

By BiotechDaily International staff writers
Posted on 01 Apr 2013
Image: The CytoSure Cancer +SNP array (4 x 180k) from Oxford Gene Technology (Photo courtesy of Oxford Gene Technology.)
Image: The CytoSure Cancer +SNP array (4 x 180k) from Oxford Gene Technology (Photo courtesy of Oxford Gene Technology.)
A novel, optimized cytogenetic cancer research microarray system enables reliable, simultaneous detection of both copy number variations (CNVs) and loss of heterozygosity (LOH), and includes software designed to facilitate superior data analysis and interpretation.

Oxford Gene Technology (OGT; Oxfordshire, UK) introduces the “CytoSure Cancer +SNP array” designed to improve the accuracy and efficiency of molecular cancer research. The new microarray combines long oligo array comparative genomic hybridization (aCGH) probes with fully validated single nucleotide polymorphism (SNP) content, providing the superior detection of both CNVs) and LOH on a single chip (4 arrays of 180k spots). The array has been optimized in collaboration with Prof. Jacqueline Schoumans from the Lausanne University Hospital (Switzerland), an expert in both aCGH and cancer genomics. Unique to the proprietary CytoSure Cancer +SNP array, any reference sample can be used for analysis without changes to the standard aCGH protocol and, thanks to novel SNP probe chemistry, no restriction digest is required. The capacity to use matched samples is a particular advantage for research into genetic aberrations in cancer, enabling any constitutional abnormalities to be filtered out.

Prof. Schoumans commented, “The development of a new microarray with the capacity to detect both CNVs and LOH simultaneously was vital for improving the efficiency and quality of our research. By working very closely with the technical experts at OGT, we have constructed a new array that allows users to simultaneously screen a wide genomic background for CNVs and LOH, while also enabling in-depth CNV analysis on 1,500 known cancer-associated genes. This approach produces accurate and insightful data, with all aberrations clearly highlighted and filtered using OGT’s excellent CytoSure Interpret Software.”

“The new CytoSure Cancer +SNP array forms part of OGT’s ongoing strategy to design specialized microarrays to help increase our understanding of cancer formation and development [and to facilitate] research into more efficacious, targeted treatments,” added James Clough, Executive Vice President Commercial at OGT. The 60-mer oligonucleotide probes utilized in the array provide a high signal-to-noise ratio and highly sensitive detection; this makes them ideal for research into complex malignant tissues. With OGT’s innovative CytoSure Interpret Software, data analysis is rapid, reliable, and simple to carry out, including updated features (such as the B-allele frequency plot) that have been optimized for the identification of biologically relevant genomic variants in tumor samples.

Related Links:
Oxford Gene Technology
CytoSure Cancer +SNP array
CytoSure Interpret Software



WATERS CORPORATION

Channels

Genomics/Proteomics

view channel
Image: Electron micrograph of Hepatitis C virus purified from cell culture. Scale bar is 50 nanometers (Photo courtesy of the Center for the Study of Hepatitis C, the Rockefeller University).

Oxidized LDL Predicts Response to Interferon Treatment of Chronic Hepatitis C and May Be a Treatment Option

Oxidized low-density lipoprotein (oxLDL) in the blood was shown to predict responsiveness to interferon treatment in patients with chronic Hepatitis C virus (HCV) infection and to inhibit spread of the... Read more

Drug Discovery

view channel
Image: Molecular model of the anti-cancer drug 5-fluorouracil (Photo courtesy of Wikimedia Commons).

Novel Microcapsule Approach Reduces Toxic Side Effects of Chemotherapy

Cancer researchers have reduced chemotherapy's toxic side effects by using nanoporous capsules to transport an enzyme to the site of a tumor where it is activated by a selective heating process to convert... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

02 Jun 2015 - 03 Jun 2015
15 Jun 2015 - 18 Jun 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.